Eumedix advises MedDay on its €34M Series B financing led by Edmond de Rothschild Investment Partners
Paris, France, April 5th 2016 - MedDay, a biotechnology company focused on the treatment of neurological disorders, appointed Eumedix as its sole placement agent to organize its €34M Series B financing.
Eumedix provided its unique expertise on all aspects of corporate strategy and corporate finance. This ensured that MedDay's strategy meets all stakeholders' goals and enables MedDay to achieve its highest ambition in the coming years. Eumedix has provided similar advisory services to high potential French biotech companies such as DBV Technologies, Adocia, Poxel...
Eumedix believes that MedDay's lead product can make a difference in the life of patients suffering from Progressive Multiple Sclerosis who have been looking for a safe and effective treatment for their degenerative disease.
Eumedix provided its unique expertise on all aspects of corporate strategy and corporate finance. This ensured that MedDay's strategy meets all stakeholders' goals and enables MedDay to achieve its highest ambition in the coming years. Eumedix has provided similar advisory services to high potential French biotech companies such as DBV Technologies, Adocia, Poxel...
Eumedix believes that MedDay's lead product can make a difference in the life of patients suffering from Progressive Multiple Sclerosis who have been looking for a safe and effective treatment for their degenerative disease.
This transaction underlines Eumedix' capabilities to advise the best companies to achieve their most ambitious global strategies.
See MedDay's press release for more
“As always, it has been a pleasure to work with Eumedix, a corporate finance advisor that is consistently giving honest and insightful advices and helps us execute it. This is so rare in this business”
|  Jacques Seguin Founder and Chairman of CoreValve (sold to Medtronics +800m$) and Stentys (EPA:STNT) Eumedix completed 7 transactions for CoreValve and Stentys.  Pierre-Henri Benhamou DBV's CEO asked Alain Lostis to join his executive team and lead investor to "ring the bell" for the first day of DBV's trading on Euronext. In his speech, he underlined Eumedix dedication to advise DBV on its last financing round as well as its critical role in the IPO success. Eumedix completed 2 critical transactions for DBV Technologies. |